BioPharma Dive23h
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
BioPharma Dive5d
Vertex challenger Sionna prices $191M IPO
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $407 from $402 and keeps a Sector Perform rating on the shares.
Morningstar21d
Vertex Energy, Inc. Successfully Emerges From Chapter 11 With Renewed Sustainable Capital Structure
Emerges from Chapter 11 as a Privately-Held Company under New Ownership Achieves Greatly Improved Balance Sheet and up to $100 million in Exit Financing Announces New Leadership to Support ...
Business Insider20d
Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...
Yahoo Finance21d
Vertex Energy, Inc. Successfully Emerges From Chapter 11 With Renewed Sustainable Capital Structure
HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...